IFF Stock Analysis: International Flavors | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 21.864m USD | 12M Return: 37% | US4595061015 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 143M
EPS Trend: 81.0%
Qual. Beats: 0
Rev. Trend: -80.3%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
International Flavors & Fragrances Inc. (NYSE: IFF) is a New York-headquartered specialty ingredients company that manufactures and markets food, beverage, health and biosciences, scent, and related products globally, operating through four reportable segments: Taste, Food Ingredients, Health & Biosciences, and Scent. The Taste segment supplies flavor systems for savory products, beverages, sweets, and dairy, while Food Ingredients provides natural and plant-based specialty ingredients, antioxidants, anti-microbials, savory solutions, inclusion products, and protein-based formulations. The Health & Biosciences segment produces enzymes, food cultures, probiotics, and specialty ingredients for food, animal nutrition, grain processing, and home/personal care applications, and the Scent segment develops fragrance compounds and ingredients. The company was incorporated in 1909 and is classified within the Materials sector under the Specialty Chemicals sub-industry.
IFF operates a business-to-business model, selling proprietary ingredient formulations and fragrance compounds to consumer goods manufacturers rather than directly to end consumers, which is typical of the flavors and fragrances industry. The sector is highly consolidated, with a small number of global players supplying the majority of taste, scent, and functional ingredient needs to food, beverage, personal care, and pharmaceutical customers worldwide.
- Fragrance and scent segment margins expand on premium innovation
- Health & Biosciences enzymes drive growth in animal nutrition and grain processing
- Debt reduction and integration of DuPont N&B assets improves capital allocation
| Net Income: 290.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.01 > 1.0 |
| NWC/Revenue: 46.88% < 20% (prev 24.29%; Δ 22.60% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.16b > Net Income 290.0m |
| Net Debt (6.22b) to EBITDA (1.49b): 4.18 < 3 |
| Current Ratio: 2.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (257.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 37.52% > 18% (prev 36.25%; Δ 1.28% > 0.5%) |
| Asset Turnover: 38.92% > 50% (prev 43.27%; Δ -4.35% > 0%) |
| Interest Coverage Ratio: 2.88 > 6 (EBIT TTM 538.0m / Interest Expense TTM 187.0m) |
| A: 0.19 (Total Current Assets 9.09b - Total Current Liabilities 4.41b) / Total Assets 25.2b |
| B: -0.14 (Retained Earnings -3.40b / Total Assets 25.2b) |
| C: 0.02 (EBIT TTM 538.0m / Avg Total Assets 25.6b) |
| D: 1.25 (Book Value of Equity 14.0b / Total Liabilities 11.1b) |
| Altman-Z'' = 2.24 = BBB |
| DSRI: 1.01 (Receivables 1.83b/2.06b, Revenue 9.98b/11.3b) |
| GMI: 0.97 (GM 36.25% / 37.52%) |
| AQI: 0.85 (AQ_t 0.51 / AQ_t-1 0.60) |
| SGI: 0.88 (Revenue 9.98b / 11.3b) |
| TATA: -0.03 (NI 290.0m - CFO 1.16b) / TA 25.2b) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of October 04, 2026, the stock is trading at USD 82.42 with a total of 1,853,855 shares traded. Over the past week, the price has changed by -3.82%, over one month by -4.75%, over three months by -1.22% and over the past year by +36.98%.
Current recommended Stop Loss: 80.20 (which is 2.7% or 1.2 ATR below the current price).
International Flavors has received a consensus analysts rating of 4.32. Therefore, it is recommended to buy IFF.
- StrongBuy: 10
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 95.7 | 16.1% |
P/E Forward = 17.6678
P/S = 2.028
P/B = 1.5647
P/EG = 1.7672
Revenue TTM = 9.98b USD
EBIT TTM = 538.0m USD
EBITDA TTM = 1.49b USD
Long Term Debt = 4.74b USD (from longTermDebt, last quarter)
Short Term Debt = 1.05b USD (from shortTermDebt, last quarter)
Debt = 6.79b USD (from shortLongTermDebtTotal, last quarter) + Leases 544.0m
Net Debt = 6.22b USD (calculated: Debt 6.79b - CCE 569.0m)
Enterprise Value = 28.1b USD (21.9b + Debt 6.79b - CCE 569.0m)
Interest Coverage Ratio = 2.88 (Ebit TTM 538.0m / Interest Expense TTM 187.0m)
EV/FCF = 52.39x (Enterprise Value 28.1b / FCF TTM 536.0m)
FCF Yield = 1.91% (FCF TTM 536.0m / Enterprise Value 28.1b)
FCF Margin = 5.37% (FCF TTM 536.0m / Revenue TTM 9.98b)
Net Margin = 2.91% (Net Income TTM 290.0m / Revenue TTM 9.98b)
Gross Margin = 37.52% ((Revenue TTM 9.98b - Cost of Revenue TTM 6.23b) / Revenue TTM)
Gross Margin QoQ = 43.65% (prev 37.14%)
Tobins Q-Ratio = 1.12 (Enterprise Value 28.1b / Total Assets 25.2b)
Interest Expense / Debt = 2.76% (Interest Expense 187.0m / Debt 6.79b)
Taxrate = 21.65% (76.0m / 351.0m)
NOPAT = 421.5m (EBIT 538.0m * (1 - 21.65%))
Current Ratio = 2.06 (Total Current Assets 9.09b / Total Current Liabilities 4.41b)
Debt / Equity = 0.49 (Debt 6.79b / totalStockholderEquity, last quarter 14.0b)
Debt / EBITDA = 4.18 (Net Debt 6.22b / EBITDA 1.49b)
Debt / FCF = 11.60 (Net Debt 6.22b / FCF TTM 536.0m)
Total Stockholder Equity = 14.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.13% (Net Income 290.0m / Total Assets 25.2b)
RoE = 2.05% (Net Income TTM 290.0m / Total Stockholder Equity 14.1b)
RoCE = 2.85% (EBIT 538.0m / Capital Employed (Equity 14.1b + L.T.Debt 4.74b))
RoIC = 1.98% (NOPAT 421.5m / Invested Capital 21.3b)
WACC = 6.78% (E(21.9b)/V(28.7b) * Re(8.22%) + D(6.79b)/V(28.7b) * Rd(2.76%) * (1-Tc(0.22)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.07 | Cagr: 0.17%
[DCF] Terminal Value 74.84% ; FCFF base≈545.6m ; Y1≈528.2m ; Y5≈520.1m
[DCF] Fair Price = 7.59 (EV 8.15b - Net Debt 6.22b = Equity 1.94b / Shares 255.1m; r=8.35% [WACC [floored]]; 5y FCF grow -4.29% → 2.50% )
EPS Correlation: 81.01 | EPS CAGR: 7.31% | SUE: 0.19 | # QB: 0
Revenue Correlation: -80.26 | Revenue CAGR: -3.66% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.81 | Chg30d=+0.86% | Revisions=-80% | Analysts=13
EPS current Year (2026-12-31): EPS=3.28 | Chg30d=+1.03% | Revisions=-82% | GrowthEPS=-22.0% | GrowthRev=-30.4%
EPS next Year (2027-12-31): EPS=3.96 | Chg30d=+0.13% | Revisions=-69% | GrowthEPS=+20.9% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: -88% (up=1, down=38)